His primary areas of study are Internal medicine, Endocrinology, Lipoprotein, Apolipoprotein B and Lipoprotein. His Internal medicine research incorporates themes from Gastroenterology, Immunology and Cardiology. His research in Endocrinology tackles topics such as Apolipoprotein E which are related to areas like Serum amyloid A.
His studies in Lipoprotein integrate themes in fields like Proinflammatory cytokine, Cancer research, Vascular disease and Pathology. His Apolipoprotein B research is multidisciplinary, relying on both Coronary artery disease, Unstable angina, Antibody and Low-density lipoprotein. His Lipoprotein research includes themes of Framingham Risk Score, Disease, Clinical trial, Stenosis and Risk factor.
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Lipoprotein, Lipoprotein and Apolipoprotein B. His Internal medicine research incorporates elements of Gastroenterology and Cardiology. He combines topics linked to Apolipoprotein E with his work on Endocrinology.
Sotirios Tsimikas works mostly in the field of Lipoprotein, limiting it down to topics relating to In vivo and, in certain cases, Pathology, as a part of the same area of interest. The various areas that Sotirios Tsimikas examines in his Lipoprotein study include Odds ratio, Calcific aortic valve stenosis, Disease, Hazard ratio and Risk factor. Sotirios Tsimikas has included themes like Autoantibody, Atorvastatin and Molecular biology in his Apolipoprotein B study.
His primary scientific interests are in Internal medicine, Lipoprotein, Lipoprotein, Endocrinology and Apolipoprotein B. His study explores the link between Internal medicine and topics such as Cardiology that cross with problems in Hazard ratio. The Lipoprotein study combines topics in areas such as Immunology, Stroke, Disease, Myocardial infarction and Proinflammatory cytokine.
He combines subjects such as Inflammation, Plasma levels, Low-density lipoprotein and Risk factor with his study of Lipoprotein. His work on PCSK9 is typically connected to Metabolic surgery as part of general Endocrinology study, connecting several disciplines of science. His biological study spans a wide range of topics, including Autoantibody, Hypertriglyceridemia, Molecular biology, Monoclonal antibody and Gene isoform.
His primary areas of investigation include Internal medicine, Lipoprotein, Lipoprotein, Endocrinology and Cholesterol. His research links Alirocumab with Internal medicine. His Lipoprotein research includes elements of Statin, Pitavastatin, Atorvastatin and Inflammation, Immunology.
His research integrates issues of Myocardial infarction, Cardiology, Gastroenterology, Disease and Proinflammatory cytokine in his study of Lipoprotein. He has researched Endocrinology in several fields, including Erythema, Apolipoprotein E and Injection site reaction. His Cholesterol study combines topics from a wide range of disciplines, such as Evinacumab, Lomitapide and Atherosclerotic cardiovascular disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Sotirios Tsimikas;Emmanouil S. Brilakis;Elizabeth R. Miller;Joseph P. McConnell.
The New England Journal of Medicine (2005)
Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity
Yury I. Miller;Soo Ho Choi;Philipp Wiesner;Longhou Fang.
Circulation Research (2011)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J Viney;Julian C van Capelleveen;Richard S Geary;Shuting Xia.
The Lancet (2016)
The role of oxidized phospholipids in atherosclerosis
Judith A. Berliner;Norbert Leitinger;Sotirios Tsimikas.
Journal of Lipid Research (2009)
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress
David Weismann;Karsten Hartvigsen;Karsten Hartvigsen;Karsten Hartvigsen;Nadine Lauer;Keiryn L. Bennett.
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
Sotirios Tsimikas;Claes Bergmark;Reinaldo W Beyer;Raj Patel.
Journal of the American College of Cardiology (2003)
Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress
Tracie A. Seimon;Marissa J. Nadolski;Xianghai Liao;Jorge Magallon.
Cell Metabolism (2010)
Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses
Nathanael J. Spann;Lana X. Garmire;Jeffrey G. McDonald;David S. Myers.
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies
Journal of the American College of Cardiology (2017)
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor–deficient mice
Galina K. Sukhova;Yaou Zhang;Jie Hong Pan;Youichiro Wada.
Journal of Clinical Investigation (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: